Toll Free: 1-888-928-9744

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 782 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2016', provides an overview of the Chronic Lymphocytic Leukemia (CLL) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
- The report reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Lymphocytic Leukemia (CLL) therapeutics and enlists all their major and minor projects
- The report assesses Chronic Lymphocytic Leukemia (CLL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL)


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 7 Chronic Lymphocytic Leukemia (CLL) Overview 8 Therapeutics Development 9 Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies 11 Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes 19 Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance 21 Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies 25 Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes 38 Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development 40 Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment 131 Drug Profiles 157 Chronic Lymphocytic Leukemia (CLL) - Recent Pipeline Updates 498 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects 738 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products 750 Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones 752 Appendix 762
List of Tables
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2016 28 Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016 29 Number of Products under Development by Companies, H1 2016 31 Number of Products under Development by Companies, H1 2016 (Contd..1) 32 Number of Products under Development by Companies, H1 2016 (Contd..2) 33 Number of Products under Development by Companies, H1 2016 (Contd..3) 34 Number of Products under Development by Companies, H1 2016 (Contd..4) 35 Number of Products under Development by Companies, H1 2016 (Contd..5) 36 Number of Products under Development by Companies, H1 2016 (Contd..6) 37 Number of Products under Investigation by Universities/Institutes, H1 2016 39 Comparative Analysis by Late Stage Development, H1 2016 40 Comparative Analysis by Clinical Stage Development, H1 2016 41 Comparative Analysis by Early Stage Development, H1 2016 42 Comparative Analysis by Unknown Stage Development, H1 2016 43 Products under Development by Companies, H1 2016 44 Products under Development by Companies, H1 2016 (Contd..1) 45 Products under Development by Companies, H1 2016 (Contd..2) 46 Products under Development by Companies, H1 2016 (Contd..3) 47 Products under Development by Companies, H1 2016 (Contd..4) 48 Products under Development by Companies, H1 2016 (Contd..5) 49 Products under Development by Companies, H1 2016 (Contd..6) 50 Products under Development by Companies, H1 2016 (Contd..7) 51 Products under Development by Companies, H1 2016 (Contd..8) 52 Products under Development by Companies, H1 2016 (Contd..9) 53 Products under Development by Companies, H1 2016 (Contd..10) 54 Products under Development by Companies, H1 2016 (Contd..11) 55 Products under Development by Companies, H1 2016 (Contd..12) 56 Products under Investigation by Universities/Institutes, H1 2016 57 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 58 Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2016 59 Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc., H1 2016 60 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 61 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corporation, H1 2016 62 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc., H1 2016 63 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H1 2016 64 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H1 2016 65 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 66 Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2016 67 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Baliopharm AG, H1 2016 68 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H1 2016 69 Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene, Ltd., H1 2016 70 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 71 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biogen, Inc., H1 2016 72 Chronic Lymphocytic Leukemia (CLL) - Pipeline by BioInvent International AB, H1 2016 73 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionovis SA, H1 2016 74 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 75 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H1 2016 76 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H1 2016 77 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectis S.A., H1 2016 78 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celltrion, Inc., H1 2016 79 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 80 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Clonz Biotech Private Limited, H1 2016 81 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Coherus BioSciences, Inc., H1 2016 82 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 83 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Company, H1 2016 84 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Emergent BioSolutions Inc., H1 2016 85 Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 86 Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd., H1 2016 87 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech, Inc., H1 2016 88 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genor BioPharma Co., Ltd., H1 2016 89 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H1 2016 90 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional, S.A., H1 2016 91 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H1 2016 92 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics S.A., H1 2016 93 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics, Inc., H1 2016 94 Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H1 2016 95 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H1 2016 96 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H1 2016 97 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 98 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Limited, H1 2016 99 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H1 2016 100 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics, Inc., H1 2016 101 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Johnson & Johnson, H1 2016 102 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H1 2016 103 Chronic Lymphocytic Leukemia (CLL) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 104 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H1 2016 105 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 106 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma, Inc., H1 2016 107 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lead Discovery Center GmbH, H1 2016 108 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Les Laboratoires Servier SAS, H1 2016 109 Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H1 2016 110 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016 111 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc., H1 2016 112 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MEI Pharma, Inc., H1 2016 113 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MENTRIK Biotech, LLC, H1 2016 114 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck & Co., Inc., H1 2016 115 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Merck KGaA, H1 2016 116 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 117 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Mirna Therapeutics, Inc., H1 2016 118 Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H1 2016 119 Chronic Lymphocytic Leukemia (CLL) - Pipeline by NantKwest, Inc., H1 2016 120 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H1 2016 121 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H1 2016 122 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 123 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Panacea Biotec Limited, H1 2016 124 Chronic Lymphocytic Leukemia (CLL) - Pipeline by PEP-Therapy SAS, H1 2016 125 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Pharmacyclics, Inc., H1 2016 126 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Plexxikon Inc., H1 2016 127 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Polyphor Ltd., H1 2016 128 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 129 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Respiratorius AB, H1 2016 130 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Revitope Oncology, Inc., H1 2016 131 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sandoz International GmbH, H1 2016 132 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H1 2016 133 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Selvita S.A., H1 2016 134 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Simcere Pharmaceutical Group, H1 2016 135 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sorrento Therapeutics, Inc., H1 2016 136 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Supratek Pharma Inc., H1 2016 137 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 138 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Targazyme, Inc., H1 2016 139 Chronic Lymphocytic Leukemia (CLL) - Pipeline by TG Therapeutics, Inc., H1 2016 140 Chronic Lymphocytic Leukemia (CLL) - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016 141 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Theravectys SA, H1 2016 142 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 143 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 144 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 145 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Trillium Therapeutics Inc., H1 2016 146 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Unum Therapeutics, Inc., H1 2016 147 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Viralytics Ltd., H1 2016 148 Chronic Lymphocytic Leukemia (CLL) - Pipeline by Zymeworks Inc., H1 2016 149 Assessment by Monotherapy Products, H1 2016 150 Assessment by Combination Products, H1 2016 151 Number of Products by Stage and Target, H1 2016 153 Number of Products by Stage and Mechanism of Action, H1 2016 164 Number of Products by Stage and Route of Administration, H1 2016 173 Number of Products by Stage and Molecule Type, H1 2016 175 Chronic Lymphocytic Leukemia (CLL) Therapeutics - Recent Pipeline Updates, H1 2016 517 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H1 2016 757 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H1 2016 758 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..2), H1 2016 759 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..3), H1 2016 760 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..4), H1 2016 761 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..5), H1 2016 762 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..6), H1 2016 763 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..7), H1 2016 764 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..8), H1 2016 765 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..9), H1 2016 766 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..10), H1 2016 767 Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..11), H1 2016 768 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H1 2016 769 Chronic Lymphocytic Leukemia (CLL) - Discontinued Products (Contd..1), H1 2016 770


List of Figures
Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2016 28 Number of Products under Development for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H1 2016 29 Number of Products under Development by Companies, H1 2016 30 Number of Products under Investigation by Universities/Institutes, H1 2016 38 Comparative Analysis by Late Stage Development, H1 2016 40 Comparative Analysis by Clinical Stage Development, H1 2016 41 Comparative Analysis by Early Stage Products, H1 2016 42 Assessment by Monotherapy Products, H1 2016 150 Assessment by Combination Products, H1 2016 151 Number of Products by Top 10 Targets, H1 2016 152 Number of Products by Stage and Top 10 Targets, H1 2016 152 Number of Products by Top 10 Mechanism of Actions, H1 2016 163 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 163 Number of Products by Top 10 Routes of Administration, H1 2016 172 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 172 Number of Products by Top 10 Molecule Types, H1 2016 174 Number of Products by Stage and Top 10 Molecule Types, H1 2016 174

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing ap

Read More...

Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecast

Read More...

Global embedded system market is projected to be valued at USD 214.39 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising demand from end-use industries such as automotive and healthcare coupled with emergence of Internet o

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify